Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice

Diabetes and Metabolism

Volumn 41, Issue 3, 2015, Pages 208-215

  Lee, Y H ^a   Lee, C J ^b   Lee, H S ^a   Choe, E Y ^c   Lee, B W ^a   Ahn, C W ^a   Cha, B S ^a   Lee, H C ^a   Balkau, B ^d   Kang, E S ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

Chronic kidney disease; Gliclazide; Glimepiride; Type 2 diabetes

Indexed keywords

CREATININE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; PROPENSITY SCORE; RISK ASSESSMENT; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; KAPLAN MEIER METHOD; MORTALITY; RETROSPECTIVE STUDY;

COHORT STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 84937641561     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.01.004     Document Type: Article

References (29)

1. Renal Data U.S., System USRDS 2011 Annual Data Report: Chapter: Incidence, Prevalence, Patient Charateristics and Treatment Modalities 2011, National Institutes of Health, National Institute of Diabetes and Kidney Diseases, Bethesda, MD.
2. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145-1151.
3. Fox C.S., Matsushita K., Woodward M., Bilo H.J., Chalmers J., Heerspink H.J., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012, 380:1662-1673.
4. Prospective Diabetes Study (UKPDS) Group UK Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
5. Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013, 83:517-523.
6. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
7. Advance Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood-glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
8. American Diabetes, Association., Standards of medical care in, diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
9. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010, 55:835-847.
10. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32:1900-1908.
11. Levey A.S., Cattran D., Friedman A., Miller W.G., Sedor J., Tuttle K., et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009, 54:205-226.
12. Messerli F.H., Staessen J.A., Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J 2010, 31:2205-2208.
13. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
14. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
15. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
16. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
17. Bo S., Castiglione A., Ghigo E., Gentile L., Durazzo M., Cavallo-Perin P., et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol 2013, 169:117-126.
18. Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes care 2010, 33:1224-1229.
19. Avogaro A. Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes Obes Metab 2012, 14(Suppl 1):14-19.
20. Chen L.L., Yu F., Zeng T.S., Liao Y.F., Li Y.M., Ding H.C. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur J Pharmacol 2011, 659:296-301.
21. Onozato M.L., Tojo A., Goto A., Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int 2004, 65:951-960.
22. Jennings P.E., Belch J.J. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism 2000, 49:23-26.
23. Chugh S.N., Dhawan R., Kishore K., Sharma A., Chugh K. Glibenclamide vs gliclazide in reducing oxidative stress in patients of non-insulin dependent diabetes mellitus-a double-blind randomized study. J Assoc Phys India 2001, 49:803-807.
24. Scott N.A., Jennings P.E., Brown J., Belch J.J. Gliclazide: a general free radical scavenger. Eur J Pharmacol 1991, 208:175-177.
25. Forbes J.M., Coughlan M.T., Cooper M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
26. Small D.M., Coombes J.S., Bennett N., Johnson D.W., Gobe G.C. Oxidative stress, antioxidant therapies and chronic kidney disease. Nephrology 2012, 17:311-321.
27. Fan Z.J., Lackland D.T., Lipsitz S.R., Nicholas J.S. The association of low birthweight and chronic renal failure among Medicaid young adults with diabetes and/or hypertension. Public Health Rep 2006, 121:239-244.
28. Kidney Disease: Improving Global Outcomes (KDIGO), KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007, 49:S12-S154.
29. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.